Recently, Ely Lilly and Company created a selective fully human IgG4 mAb, tabalumab (LY2127399), with neutralizing activity against both membrane-bound and soluble BAFF.77 In murine xenograft models, tabalumab showed an anti-MM effect and inhibits osteoclastogenesis.44 In a phase I study, tabalumab was evaluated combined with bortezomib in relapsed or refractory MM patients. This evidence concerns the gene TNFSF13B and Miyoshi myopathy.